GlobeNewswire Inc.··NaKyverna's Miv-cel Shows Durable Benefits in Stiff Person Syndrome Trial
Kyverna's miv-cel shows statistically significant benefits across all endpoints in stiff person syndrome trial, with 81% achieving meaningful walking speed improvement.
KYTXclinical trialautoimmune disease